Testimony of Pat Furlong Founding President - Duchenne de Boulogne - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-07-10 09:41:25 Pharmaceutical sciences Pharmacology Muscular Dystrophy Community Assistance Research and Education Amendments Food and Drug Administration Alternative medicine Clinical trial Genetic disorder Duchenne muscular dystrophy Duchenne de Boulogne Muscular dystrophy Health Medicine		Testimony of Pat Furlong Founding President & CEO Parent Project Muscular Dystrophy Committee on Energy & Commerce Subcommittee on Health July 11, 2014 Add to Reading List Source URL: docs.house.gov Download Document from Source Website File Size: 80,87 KB Share Document on Facebook

	PROUD PROUD Participant Involvement meeting: Trial Design Date: Tuesday 9th September – 20.00 Venue: MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, Holborn, WC2B 6NH Contact person: Mitzy Gaf DocID: 1vq4y - View Document
	Clinical Review & Education JAMA \| Special Communication Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols DocID: 1vmrb - View Document
	For immediate release March 21, 2017 Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis Moscow, Russia and Rockville, MD, USA -- Infecte DocID: 1vkmw - View Document
	DEPARTMENT OF HEALTH DRUG OFFICE DRUG REGISTRATION AND IMPORT/EXPORT CONTROL DIVISION Guidance Notes on the Application for Certificate for Clinical Trial/Medicinal Test Background DocID: 1vkj3 - View Document
	CLINICAL TRIAL OUTCOME DATABASE (CTOD) Novartis RA: Longitudinal Model-Based Meta-Analysis in Rheumatoid Arthritis: An Application Toward Model-Based Drug Development Authors I Demin, B Hamren, O Luttringer, G Pillai and DocID: 1vbDv - View Document